Clozapine Bootcamp: Why, When and How to Use this Evidence Based Treatment



Date & Location
Wednesday, January 1, 2025, 7:00 AM - Wednesday, December 31, 2025, 1:00 PM

Overview

 

This course is designed to equip healthcare professionals with the knowledge and skills necessary to navigate the complexities of clozapine management. Participants will delve into the challenging logistics of clozapine use, including the intricacies of the clozapine REMS (Risk Evaluation and Mitigation Strategy) program, and the management challenges associated with transitions of care, contraindications, and barriers to use.
The course will provide a comprehensive understanding of clozapine pharmacology, efficacy, and indications for use. Participants will learn effective communication strategies for discussing clozapine treatment with patients and their families, as well as gain insights into treatment guidelines, dosing, titration, and augmentation strategies.


In addition, the course will build confidence and competence in identifying, mitigating, and treating adverse events, with a focus on both common and rare side effects. Through case studies and discussions, participants will refine their proficiency in all aspects of clozapine care, enabling them to apply their knowledge and experience to improve patient outcomes.


This course is essential for healthcare providers seeking to deepen their expertise in clozapine management and enhance their clinical practice in the treatment of patients requiring this complex medication.


Disclosure: It is the policy of the University of Maryland School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities.  In accordance with this policy, all persons in a position to control the educational content of this educational activity must disclose any relevant financial relationships they have with ineligible companies. None of the planners/speakers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Discussion of Off-Label or Investigational Uses 
Presentations in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices.  The audience is advised to consult the full prescribing information of all drugs or devices prior to use. Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings.  The FDA has stated that it is the responsibility of the prescribing health care professional to determine the FDA status of each drug or device that he/she wishes to use in clinical practice, and to use the products in compliance with applicable law.

UMSOM requires that all contributors disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use.  Physicians and other healthcare professionals are urged to fully review all the available data on products or procedures before using them to treat patients.
Disclaimer

This CME activity is designed for use by healthcare professionals for educational purposes only.  Information and opinions offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information. 

While UMSOM makes every effort to have accurate information presented, no warranty, express or implied, is offered with respect to the information presented. Each participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information provided in this CME activity.

 


Accreditation

The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Maryland School of Medicine designates this Live activity for a maximum of 17.25 AMA PRA Category 1 Credits TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Credits
AMA PRA Category 1 Credits™ (17.25 hours), Non-Physician Attendance (17.25 hours)